News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Rare Disease Biotech Bio Blast Pharma Sets Terms For $40 Million IPO


7/16/2014 6:48:38 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

Cerus Corporation Secures $30 Million Growth Capital Credit Facility From Oxford Finance

Bio Blast Pharma, a clinical-stage biotech developing treatments for rare and ultra-rare genetic diseases, announced terms for its IPO on Tuesday. The Tel Aviv, Israel-based company plans to raise $40 million by offering 3.3 million shares at a price range of $11 to $13. At the midpoint of the proposed range, Bio Blast would command a fully diluted market value of $178 million.

Bio Blast Pharma, which was founded in 2012, plans to list on the NASDAQ under the symbol ORPN. Oppenheimer and Roth Capital are the joint bookrunners on the deal.

Help employers find you! Check out all the jobs and post your resume.

Read at Nasdaq

comments powered by Disqus
Nasdaq
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES